secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akari Therapeutics Plc (AKTX)
CIK:        0001541157
Form:       8-K
Filed at:   2025-07-01T23:59:59+00:00
Accession:  0000950170-25-092350
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Akari shareholder-approved 11B share increase for equity plan and director option grant of 1.35M ADSs
--------------------------------------------------------------------------------

- Shareholders approved increase in 2023 Plan share pool by 11,026,000,000 ordinary shares (5,513,000 ADSs) to 19,806,000,000 ordinary shares.
- Approved aggregate time-vested option grant of 1,350,000 ADSs (2.7B ordinary shares) to six directors, representing 4.2% of issued share capital.
- Re-elected all six director nominees: Hoyoung Huh, Robert Bazemore, James Neal, Sandip Patel, Samir Patel, Abizer Gaslightwala.
- Ratified BDO USA as independent auditor for FY2025 and HaysMac as statutory auditor.
- Advisory votes on NEO compensation and board remuneration report passed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1541157/000095017025092350/0000950170-25-092350-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1541157/000095017025092350/aktx-20250630.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-092350

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer